🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chemnitz
Clinical trial register · Germany

Clinical Trials in Chemnitz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 Hoffmann-La Roche10 Bristol-Myers Squibb7 AbbVie6 Eli Lilly and Company5
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Chemnitz

166 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Freiburg im Breisgau, Heidelberg, Mutlangen, Minden, Koblenz, Chemnitz, Halle, Jena
2026-09-02
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Ahrensburg, Bad Mergentheim, Bad Nenndorf, Berlin, Bonn, Brandenburg an der Havel, Braunschweig, Chemnitz
2026-08-21
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Berlin, Chemnitz, Hamburg, Leipzig, Schwerin
2026-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Bad Oeynhausen, Berlin, Chemnitz, Damme, Duisburg, Elsterwerda, Erlangen, Essen
2026-07-06
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Recruiting
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
NCT07424261Lupus Erythematosus, Systemic
AstraZeneca
Observational
125
Altenburg, Bad Bramstedt, Berlin, Braunschweig, Chemnitz, Erlangen, Heidelberg, Herne
2026-03-19
Recruiting
EASY Algorithm Trial (Elbow Trauma Assessment Using Sonography in Children and Youth) Diagnostic Accuracy and Safety of Point-of-care Ultrasound as a Screening Tool for Suspected Elbow Fractures in Children Aged 5 to 15 Years: a Multicenter Prospective Cohort Study
NCT07429344Elbow Fractures, Distal Humerus Fracture, Pediatric Trauma, Radius Fracture
Timo Munz
Observational
543
Amberg, Berlin, Chemnitz, Dresden, Duisburg, Freiburg im Breisgau, Hamburg, Kassel
2026-03-02
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Aachen, Berlin, Bielefeld, Chemnitz, Mainz, Mannheim, Schwerin, Siegen
2026-02-09
Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
NCT07025824AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
DrugsTreosulfan·Melphalan·Fludarabine
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164Neuroendocrine Tumors
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
NCT07270991Metastatic Oesogastric Adenocarcinoma
DrugsTrifluridine/Tipiracil·Fruquintinib
Federation Francophone de Cancerologie Digestive
Phase 3
324
Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock
2025-12-15
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542Neovascular Age-related Macular Degeneration
DrugRanibizumab
Hoffmann-La Roche
Phase 3
250
Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg
2025-11-27
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Düsseldorf, Herne, Minden, Chemnitz, Jena
2025-11-25
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Cisplatin·Pembrolizumab
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg
2025-10-17
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Chemnitz
2025-09-02
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898Neoplasms, Lung
DrugsRis-Rez·Topotecan
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck, München
2025-08-11
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
Ulm, Gröbenzell, Traunstein, Giessen, Kassel, Koblenz, Chemnitz, Halle
2025-07-23
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-06-19
Recruiting
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958AML, MDS
DrugIvosidenib
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Bad Bentheim, Bonn, Chemnitz, Dresden, Frankfurt, Göttingen, Kiel, Mainz
2025-06-17
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Recruiting
A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)
NCT06656988Peripheral Vascular Diseases, Kidney Diseases
University of Leipzig
Phase 3
1,960
Alsfeld, Bad Krozingen, Bonn, Chemnitz, Flensburg, Frankfurt a.M., Leipzig, München
2025-04-14
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
Berlin, Chemnitz
2025-04-04
Not yet open
App Impact on Quality of Life and Symptoms in PCOS
NCT06912594Polycystic Ovary Syndrome (PCOS)
Endo Health GmbH
Not applicable
220
Chemnitz
2025-04-02
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
Freiburg im Breisgau, Bad Bentheim, Merzig, Chemnitz, Quedlinburg, Hamburg
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf
2025-03-27
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Active, closed
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT06731803Esophagogastric Adenocarcinoma
DrugTrastuzumab deruxtecan
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Recruiting
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT05099471Waldenstrom Macroglobulinemia, Treatment Naive
DrugsVenetoclax·Rituximab
Christian Buske
Phase 2
80
Bielefeld, Chemnitz, Kempten, Kiel, Koblenz, Landshut, Mönchengladbach, Mutlangen
2025-03-21
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Chemnitz, Frankfurt am Main, Halle, Hamburg, Mutlangen, München, Siegen
2025-03-05
Active, closed
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT06680622Metastatic Gastro-esophageal Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
126
Aachen, Amberg, Augsburg, Bad Saarow, Berlin, Bielefeld, Chemnitz, Dortmund
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Augsburg, Bad Saarow, Berlin, Braunschweig, Chemnitz, Düsseldorf, Erlangen, Essen
2025-03-01
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Chemnitz, Esslingen am Neckar, Gauting, Giesen, Halle, Herne, Karlsruhe, Minden
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Recruiting
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT06686615Primary Hypercholesterolemiia, Mixed Dyslipidemia
DrugsBempedoic acid·Ezetimibe·Rosuvastatin·Atorvastatin
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,000
Aachen, Ahaus, Alsfed, Bad Homburg, Berlin, Burg, Chemnitz, Detmold
2025-02-12
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Erbach im Odenwald, Westerstede, Greifswald, Bielefeld, Ibbenbueren, Siegen, Chemnitz, Leipzig
2025-02-10
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Chemnitz, Dresden, Mainz, München, Regensburg
2024-12-16
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Berlin, Chemnitz, Essen, Jena, Würzburg
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
346
Aachen, Buxtehude, Chemnitz, Darmstadt, Dresden, Frankfurt am Main, Göttingen, Magdeburg
2024-10-10
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Westerstede
2024-10-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
DrugsEndoxan·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 2
95
Regensburg, Chemnitz, Dresden
2024-08-30
Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Universitätsklinikum Hamburg-Eppendorf
Not applicable
130
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck
2024-08-30
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Mvasi·Sotorasib·Panitumumab
Amgen
Phase 3
450
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Hamburg, Ludwigsburg, München
2024-07-17
Recruiting
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
NCT06494540Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca
Observational
600
Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt
2024-06-28
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Augsburg, Bielefeld, Chemnitz, Frankfurt, Freiburg im Breisgau, Halle, Hamburg, Kiel
2024-06-26
Active, closed
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
DrugsTemodar·Niraparib·Temozolomide
Ivy Brain Tumor Center
Phase 3
450
Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin
2024-06-19
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Chemnitz, Hamburg, Heidelberg, Würzburg
2024-06-07
Active, closed
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122Follicular Lymphoma
DrugsBendamustin·Vincrystine·Mosunetuzumab·Obinutuzumab
The Lymphoma Academic Research Organisation
Phase 3
790
Amberg, Bamberg, Berlin, Bremen, Chemnitz, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-06-07
Recruiting
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
NCT06474806Prostate Cancer
Curasight
Phase 2
168
Chemnitz, Düsseldorf, Hamburg, Munich
2024-06-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Chemnitz, Frankfurt, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-05-24
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Freiburg im Breisgau, Karlsruhe, Chemnitz, Berlin, Frankfurt am Main, Hamburg
2024-05-19
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Bad Nauheim, Bechhofen, Berlin, Bernau bei Berlin, Chemnitz, Coburg, Dresden, Elsterwerda
2024-04-12
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Heidelberg, Bad Doberan, Greifswald Hansestadt, Chemnitz, Hamburg
2024-04-08
Recruiting
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
NCT05904106Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Active, closed
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158Multiple Myeloma
DrugsIberdomide·Isatuximab·Dexamethasone
University of Heidelberg Medical Center
Phase 3
411
Aachen, Augsburg, Bad Saarow, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz
2024-04-05
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Chemnitz, Frankfurt am Main, Freiburg im Breisgau, Hanover, Homburg, Münster
2024-03-13
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
NCT06377462VEXAS Syndrome
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Recruiting
Eye Diseases "Treated" With Interoperable Medical Informatics
NCT06810011Intravitreal Injections
University Hospital Muenster
Observational
2,000
Chemnitz, Aachen, Greifswald, Leipzig, Münster, Tübingen
2024-03-01
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsTemodal·Lomustine·Temozolomide·Carboplatin
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Active, closed
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
NCT06087627Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
110
Adernach, Berlin, Chemnitz, Düren, Düsseldorf, Hamburg, Leipzig, Mainz
2023-12-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2023-12-21
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.
Observational
900
Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg
2023-12-18
Active, closed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
DrugAxatilimab
Syndax Pharmaceuticals
Phase 2
145
Konstanz, Munich, Hanover, Chemnitz, Frankfurt am Main, Gauting, Rosenheim
2023-12-11
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Chemnitz, Gauting, Göttingen, Kempten, München
2023-11-16
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Freiburg, Göttingen, Essen, Chemnitz, Dresden, Hamburg
2023-11-12
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
By invitation
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
NCT05883748Erythropoietic Protoporphyria
DrugBitopertin
Disc Medicine, Inc
Phase 2/3
230
Berlin, Chemnitz
2023-08-31
Active, closed
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05771480Biliary Tract Cancer
DrugsAlbumin-Bound Paclitaxel·Tegafur·Durvalumab·Oxaliplatin
AstraZeneca
Phase 3
142
Chemnitz, Hanover
2023-08-16
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT05853965Multiple Myeloma, Multiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2
45
Hamburg, Chemnitz, Heidelberg, Lübeck, Ulm
2023-06-28
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Ulm, Augsburg, Bayreuth, Erlangen, Munich, Cottbus, Hamburg, Chemnitz
2023-06-22
Active, closed
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
NCT05833438Acute Myeloid Leukemia (AML)
University of Leipzig
Phase 2
45
Berlin, Chemnitz, Cottbus, Dresden, Heidelberg, Leipzig, Mönchengladbach, München
2023-05-17
Active, closed
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156Lymphoma, Large B-Cell, Diffuse
DrugsPolatuzumab Vedotin·Glofitamab·Obinutuzumab·Rituximab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Active, closed
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
NCT06039241Atopic Dermatitis
Sanofi
Observational
572
Aachen, Ahaus, Andernach, Berlin, Braunschweig, Buxtehude, Chemnitz, Cologne
2023-03-07
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich
2023-01-11
Recruiting
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT05306041HER2-positive Breast Cancer
DrugsPhesgo·Inavolisib
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Rows per page Showing 1–100 of 166
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/chemnitz

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 166 of those studies with a site in Chemnitz.

How many clinical trials are recruiting in Chemnitz?

90 of the 166 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 3 have not yet opened recruitment, 71 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chemnitz), 166 studies
PhaseStudiesRecruitingShare
Phase 3944756.6%
Observational262015.7%
Phase 2251215.1%
Phase 2/3955.4%
Phase 1/2633.6%
Not applicable432.4%
Phase 1100.6%
Phase 4100.6%

Most active sponsors

Lead sponsors with the most studies (Chemnitz)
Lead sponsorStudiesRecruiting
AstraZeneca2013
Hoffmann-La Roche101
Bristol-Myers Squibb73
AbbVie61
Eli Lilly and Company53
Pfizer54
Technische Universität Dresden55
Universitätsklinikum Hamburg-Eppendorf53
Amgen42
Janssen Research & Development, LLC41
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.